Literature DB >> 3523251

Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

M G Harrington, C R Merril, D M Asher, D C Gajdusek.   

Abstract

We studied more than 300 cerebrospinal fluid proteins from 21 patients with Creutzfeldt-Jakob disease. We also examined cerebrospinal fluid from 100 normal controls and more than 400 patients with various neurologic disorders other than Creutzfeldt-Jakob disease. Four abnormal proteins that were identified in the patients with Creutzfeldt-Jakob disease were absent in the normal persons. Two of these proteins (Mr [relative molecular mass], 40,000; pl [isoelectric point], 5.7 and Mr 40,000; pl 5.9) were also present in some patients with multiple sclerosis, herpes simplex encephalitis, schizophrenia, Parkinson's disease, or Guillain-Barré or Behçet's syndrome. Two proteins (Mr 26,000; pl 5.2 and Mr 29,000; pl 5.1) were present in all patients with Creutzfeldt-Jakob disease and in 5 of 10 patients with herpes simplex encephalitis, but in none of the other control groups. A subsequent blinded study of these cerebrospinal fluid proteins from patients with Creutzfeldt-Jakob disease, Alzheimer's disease, Huntington's disease, multi-infarct dementia, parkinsonism dementia of Guam, or the specific dementia of the acquired immunodeficiency syndrome resulted in the ability to distinguish all cases of Creutzfeldt-Jakob disease from the other types of dementia. Although the identity and origin of the abnormal spinal fluid proteins are not yet known, these preliminary results suggest that their presence may help in the diagnosis of Creutzfeldt-Jakob disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3523251     DOI: 10.1056/NEJM198607313150502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  9 in total

1.  Increased levels of epsilon and gamma isoforms of 14-3-3 proteins in cerebrospinal fluid in patients with Creutzfeldt-Jakob disease.

Authors:  H Takahashi; T Iwata; Y Kitagawa; R H Takahashi; Y Sato; H Wakabayashi; M Takashima; H Kido; K Nagashima; K Kenney; C J Gibbs; T Kurata
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  14-3-3 proteins in neurological disorders.

Authors:  Molly Foote; Yi Zhou
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

3.  Pituitary growth hormone and Creutzfeldt-Jakob disease.

Authors:  M E Macario; M Vaisman; A Buescu; V Moura Neto; H M Araujo; C Chagas
Journal:  BMJ       Date:  1991-05-11

4.  Problems associated with biological markers of Alzheimer's disease.

Authors:  H J Frey; K M Mattila; M A Korolainen; T Pirttilä
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

Review 5.  Two-dimensional protein electrophoresis: from molecular pathway discovery to biomarker discovery in neurological disorders.

Authors:  Leila H Choe; Brenda G Werner; Kelvin H Lee
Journal:  NeuroRx       Date:  2006-07

6.  Identification of two novel cerebrospinal fluid proteins in non specific mental retardation.

Authors:  N N Raju; M Sujatha; P P Reddy; M C Vemuri
Journal:  Neurochem Res       Date:  1991-01       Impact factor: 3.996

Review 7.  The clinical use of cerebrospinal fluid studies in demyelinating neurological diseases.

Authors:  M G Harrington; P G Kennedy
Journal:  Postgrad Med J       Date:  1987-09       Impact factor: 2.401

Review 8.  Prions and related neurological diseases.

Authors:  M Pocchiari
Journal:  Mol Aspects Med       Date:  1994

9.  Prediction and verification of the AD-FTLD common pathomechanism based on dynamic molecular network analysis.

Authors:  Meihua Jin; Xiaocen Jin; Hidenori Homma; Kyota Fujita; Hikari Tanaka; Shigeo Murayama; Hiroyasu Akatsu; Kazuhiko Tagawa; Hitoshi Okazawa
Journal:  Commun Biol       Date:  2021-08-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.